Marshall Wace’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.1M | Buy |
140,588
+116,565
| +485% | +$6.64M | 0.01% | 973 |
|
|
2025
Q4 | $1.02M | Buy |
+24,023
| New | +$1.34M | ﹤0.01% | 1914 |
|
|
2025
Q3 | – | Sell |
-14,200
| Closed | -$367K | – | 3230 |
|
|
2025
Q2 | $367K | Buy |
+14,200
| New | +$159K | ﹤0.01% | 2253 |
|
|
2024
Q2 | – | Sell |
-98,082
| Closed | -$1.37M | – | 2821 |
|
|
2024
Q1 | $1.37M | Sell |
98,082
-61,001
| -38% | -$639K | ﹤0.01% | 1526 |
|
|
2023
Q4 | $1.34M | Sell |
159,083
-36,665
| -19% | -$278K | ﹤0.01% | 1374 |
|
|
2023
Q3 | $1.76M | Buy |
+195,748
| New | +$1.88M | ﹤0.01% | 1281 |
|
|
2023
Q2 | – | Sell |
-3,593
| Closed | -$37.7K | – | 2806 |
|
|
2023
Q1 | $37.7K | Buy |
+3,593
| New | +$109K | ﹤0.01% | 2554 |
|
|
2022
Q4 | – | Sell |
-2,076
| Closed | -$100K | – | 3255 |
|
|
2022
Q3 | $100K | Buy |
+2,076
| New | +$124K | ﹤0.01% | 3183 |
|
|
2022
Q1 | – | Sell |
-2,443
| Closed | -$495K | – | 3788 |
|
|
2021
Q4 | $495K | Buy |
+2,443
| New | +$530K | ﹤0.01% | 2803 |
|
|
2021
Q3 | – | Sell |
-5,917
| Closed | -$1.52M | – | 3284 |
|
|
2021
Q2 | $1.52M | Buy |
+5,917
| New | +$1.64M | 0.01% | 1598 |
|
|
2020
Q1 | – | Sell |
-5,635
| Closed | -$1.82M | – | 1926 |
|
|
2019
Q4 | $1.82M | Buy |
+5,635
| New | +$1.63M | 0.01% | 839 |
|
|
2019
Q2 | – | Sell |
-8,248
| Closed | -$4.16M | – | 1679 |
|
|
2019
Q1 | $4.16M | Sell |
8,248
-4,126
| -33% | -$2.45M | 0.04% | 524 |
|
|
2018
Q4 | $6.1M | Buy |
+12,374
| New | +$7.47M | 0.06% | 395 |
|
|
2018
Q2 | – | Sell |
-486
| Closed | -$775K | – | 800 |
|
|
2018
Q1 | $775K | Buy |
+486
| New | +$626K | 0.03% | 287 |
|
|
2017
Q3 | – | Sell |
-1,430
| Closed | -$429K | – | 396 |
|
|
2017
Q2 | $429K | Buy |
+1,430
| New | +$413K | 0.02% | 252 |
|
|
2017
Q1 | – | Sell |
-55,332
| Closed | -$10.2M | – | 602 |
|
|
2016
Q4 | $10.2M | Buy |
55,332
+15,452
| +39% | +$3.14M | 0.07% | 329 |
|
|
2016
Q3 | $10.3M | Buy |
39,880
+24,001
| +151% | +$6.18M | 0.07% | 277 |
|
|
2016
Q2 | $3.39M | Buy |
+15,879
| New | +$3.55M | 0.03% | 477 |
|
|
2016
Q1 | – | Sell |
-21,608
| Closed | -$5.46M | – | 1142 |
|
|
2015
Q4 | $5.46M | Buy |
+21,608
| New | +$4.44M | 0.05% | 359 |
|
|
2014
Q4 | – | Sell |
-5,327
| Closed | -$964K | – | 909 |
|
|
2014
Q3 | $964K | Buy |
+5,327
| New | +$1.02M | 0.01% | 556 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Marshall Wace's NKTR Position: Q1 2026 in Review
Marshall Wace increased its Nektar Therapeutics (NKTR) stake by 485% in Q1 2026, buying an estimated $6.64M and bringing the position to 140,588 shares worth $10.1M. The position accounts for 0.01% of the portfolio, ranked #973.
Marshall Wace first reported a position in NKTR in Q3 2014 and has held it in 20 quarters since. The position peaked at $10.3M in Q3 2016. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Marshall Wace held 140,588 shares of Nektar Therapeutics worth $10.1M as of Q1 2026.
- Marshall Wace bought 116,565 Nektar Therapeutics shares in Q1 2026, an estimated $6.64M.
- Nektar Therapeutics made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #973 holding.
- Marshall Wace first reported a position in Nektar Therapeutics in Q3 2014 and has held it in 20 quarters since.
- Marshall Wace's Nektar Therapeutics position peaked at $10.3M in Q3 2016.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.